MMSI

AI Memo

Merit Medical

As of 2026-09-20/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Delivery against raised 2026 guidance • 2026-12-31

Base target: $93 / p=50% prob

Biggest risk

Year-to-date operating cash flow declined 11% and free cash flow declined 14% despite stronger revenue and earnings. The shares therefore require continued therapeutic growth, margin execution, and guidance delivery; two disclosed COO open-market sales also warrant monitoring without implying deteriorating operations. [#SEC-8K-2026-07-30] [#SEC-FORM4-2026-08-05] [#SEC-FORM4-2026-08-25]

Invalidation

Break below $72 or thesis failure.

What would change my mind?

Q2 delivered 10% reported revenue growth, 9% organic constant-currency growth, higher GAAP and non-GAAP operating margins, and an 18% increase in non-GAAP EPS. Management said results exceeded the high end of expectations and raised 2026 revenue and non-GAAP EPS guidance, supporting a case for continued estimate resilience. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

high

As of

2026-09-20

Base target

$93

p=50%

Bull target

$105

p=25%

Bear target

$72

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Therapeutic portfolio growth durability
Operational leadership and post-2026 strategy
Q2 delivered 10% reported revenue growth, 9% organic constant-currency growth, higher GAAP and non-GAAP operating margins, and an 18% increase in non-GAAP EPS.

BearKey bullets

Failure to sustain Cardiac Therapies and Endoscopy growth could expose dependence on the strongest therapeutic categories and weaken the raised-guidance case.
[#SEC-8K-2026-07-30]
Raised full-year guidance increases execution risk if procedure demand, product mix, or margins soften before year-end.

WatchKey bullets

Delivery against raised 2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $93 (p=50%)

Target spread vs base: +13% / -23%

Scenario probabilities

Bull Target: $105 (p=25%)Base Target: $93 (p=50%)Bear Target: $72 (p=25%)

Commentary

Primary-source tone remains constructive following expectation-beating Q2 results and raised 2026 guidance, but subsequent news flow is sparse. No sufficient social-sentiment, options-skew, short-interest, employee-rating, or post-print analyst-revision evidence was supplied; the corresponding zero values are unavailable-data placeholders and should not influence the thesis. The stock closed at $85.37 on September 18, below the COO's August 24 sale price, but no causal inference is warranted.

As of 2026-09-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Therapeutic portfolio growth durability
Operational leadership and post-2026 strategy

Scenarios

Bull Target (Scenario probability)

$105 / p=25% prob

Base Target (Scenario probability)

$93 / p=50% prob

Bear Target (Scenario probability)

$72 / p=25% prob

Analysis 2026-09-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Delivery against raised 2026 guidance
After Q2 revenue reached $418.8 million, organic constant-currency growth was 9%, and results exceeded the high end of management's expectations, Merit raised its full-year revenue and non-GAAP EPS guidance. Execution through year-end would reinforce estimate confidence; deceleration or a guidance reversal would challenge the thesis. [#SEC-8K-2026-07-30]
Prob 65.00% • Move 10.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Therapeutic portfolio growth durability
2026-12-31
Q2 therapeutic revenue grew 14% in constant currency, including 22% growth in Cardiac Therapies and 29% in Endoscopy. Sustaining these gains while weaker categories stabilize would improve the quality of growth, but the current valuation already reflects meaningful continuation. [#SEC-8K-2026-07-30]
Prob 60% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

Operational leadership and post-2026 strategy
2027-06-30
Sheri Lewis became Executive Vice President of Global Operations effective August 31, 2026, while management is developing a longer-term plan focused on sustainable growth and enhanced profitability. Quantified targets or demonstrable operating improvements could broaden the thesis, but the evidence currently supports monitoring rather than underwriting a step-change. [#8-K-2026-08-20] [#SEC-8K-2026-07-30]
Prob 45% • Move 7% • Priced-in 20%

Risks

Failure to sustain Cardiac Therapies and Endoscopy growth could expose dependence on the strongest therapeutic categories and weaken the raised-guidance case. [#SEC-8K-2026-07-30]
Raised full-year guidance increases execution risk if procedure demand, product mix, or margins soften before year-end. [#SEC-8K-2026-07-30]
The COO disclosed open-market sales totaling 28,949 shares in August 2026; these transactions are a monitoring signal only and do not establish an operating problem. [#SEC-FORM4-2026-08-05] [#SEC-FORM4-2026-08-25]
The supplied analyst-target dataset lacks a contributor count, low/high range, and post-earnings revision details, limiting valuation confidence.
Year-to-date operating cash flow fell 11% and free cash flow fell 14% even as Q2 earnings improved. [#SEC-8K-2026-07-30]

Peers

Symbol	Summary
ABT	Useful diversified-medtech reference for procedure demand and margins, but Abbott's diagnostics, nutrition, and pharmaceutical exposure makes it a broad rather than direct peer.
BSX	Relevant cardiovascular-device comparator, although Boston Scientific's substantially larger scale and different portfolio mix limit direct valuation comparability.
EW	Relevant procedure-driven cardiovascular comparator, though its structural-heart concentration differs materially from Merit's diversified interventional portfolio.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-20

Loading AI feed…

Symbol

Summary

ABT

Useful diversified-medtech reference for procedure demand and margins, but Abbott's diagnostics, nutrition, and pharmaceutical exposure makes it a broad rather than direct peer.

BSX

Relevant cardiovascular-device comparator, although Boston Scientific's substantially larger scale and different portfolio mix limit direct valuation comparability.

Relevant procedure-driven cardiovascular comparator, though its structural-heart concentration differs materially from Merit's diversified interventional portfolio.